REDX 08397
Alternative Names: REDX08397Latest Information Update: 28 Jun 2022
At a glance
- Originator Redx Pharma
- Class Antifibrotics
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Fibrosis in United Kingdom
- 09 Oct 2018 Redx Pharma plans to conduct CTA/IND enabling studies of REDX 08397 for Crohn's disease associated fibrosis (Redx Pharma pipeline, October 2018)
- 30 May 2018 Redx Pharma has patent protection for Pan-ROCK inhibitor in USA before May 2018